Igc Pharma Inc (IGC)

$0.28 +0.01 (2.26%)
Market Cap 28.12M
Revenue (ttm) 1.27M
Net Income (ttm) -7.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.15
Volume 441,400
Avg Vol 699,906
Day's Range N/A - N/A
Shares Out 100.09M
Stochastic %K 76%
Beta 0.45
Analysts Sell
Price Target $4.25

Company Profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MI...

Industry: Biotechnology
Sector: Healthcare
Phone: 301 983 0998
Address:
10224 Falls Road, Potomac, United States
GordoHLYK13
GordoHLYK13 Jul. 4 at 1:44 PM
$IGC $IGC is building serious momentum. 🔥 Phase 2 CALMA is fully enrolled (146 patients), most participants have already completed the study, and the next big catalyst is the topline data readout. If results are positive, this could be a game-changing moment. Meanwhile, TGR-63 remains a promising Alzheimer’s pipeline asset, with management expected to accelerate updates after CALMA. Add in IGC’s expanding AI platform, insider alignment, and upcoming catalysts, and the setup keeps getting stronger. Eyes on CALMA. The biggest move could still be ahead. 🚀🧠💰 $IGC $LLY $BIIB $JNJ $MRK
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 8:13 AM
$IGC Bullish: CEO and PFO just converted $1.15M of debt into equity at $0.27/share instead of taking cash. That’s serious skin in the game. Their restricted Rule 144 shares mean no immediate insider dumping pressure. Balance sheet is stronger, cash is preserved, and insiders look locked & loaded ahead of the Phase 2 CALMA trial results. If the data is positive, expect a lot more eyes on igc 👀🚀 Tags: $LLY $JNJ $PFE $MRK
1 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 8:13 AM
$IGC CEO and PFO just converted $1.15M of debt into equity at $0.27/share instead of taking cash. That’s real skin in the game. Those are restricted Rule 144 shares, so there’s no immediate insider dumping pressure. They cleaned up the balance sheet, preserved cash, and look locked & loaded ahead of the upcoming Phase 2 CALMA trial results. Insiders don’t increase their equity exposure by millions of shares unless they see potential upside—but clinical trial outcomes remain uncertain until the data is released. 🚀📈 https://www.getnews.info/story/2026/07/01/igc-pharma-nyse-igc-ceo-and-cfo-acquire-more-than-42-million-shares/ $LLY $JNJ $PFE $MRK
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 3 at 6:02 PM
$IGC Not hype—just facts. 🔥 CEO & CFO converted $1.15M of debt into restricted shares, increasing insider alignment while reducing debt. With a tight float, institutional ownership, the upcoming AAIC London AI showcase, and the Phase 2 CALMA data catalyst ahead, IGC is lining up multiple potential catalysts. If the news delivers, this micro-cap could get a lot more attention. 🚀📈 $IGC #Biotech #Alzheimers #AI #SmallCaps
0 · Reply
angel6
angel6 Jul. 3 at 5:48 AM
$IGC when will the read out report be released?
1 · Reply
RocketQueen
RocketQueen Jul. 2 at 8:26 PM
$IGC good to see the CEO and CFO in FOMO mode...
0 · Reply
MrTicker
MrTicker Jul. 2 at 8:09 PM
$IGC a little volume bump after hours.. its a long weekend as the market is closed tomorrow so this could see some attention.
1 · Reply
RocketQueen
RocketQueen Jul. 2 at 6:05 PM
$IGC starting the long trail up to over 5.00 with positive results from the CALMA trial.
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 2 at 2:23 PM
$BIIB $IGC $LLY $MRK $PFE $IGC the share price is climbing because buyers are positioning ahead of the Phase 2 CALMA data. Smart money often looks to get in before potential catalysts—not after them. If CALMA delivers positive results, today’s prices could look like a bargain. 🚀🧠 #IGC #Alzheimers #Biotech
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 2 at 11:53 AM
$IGC IGC is entering its biggest catalyst yet. 🚀 Phase 2 CALMA enrollment is complete, all 146 patients are locked in, and now the market is waiting for the data. The enrollment risk is gone—it’s all about the readout. IGC-AD1 targets Alzheimer’s-related agitation, a multi-billion-dollar unmet market with very few effective treatment options. If the Phase 2 results are positive, IGC could quickly move onto the radar for licensing, partnerships, or acquisition discussions. What makes this even more interesting? IGC has funded its own clinical development, giving it flexibility if the data is strong. Positive results could attract interest from biotech and pharma leaders looking to expand their neuroscience pipelines. $LLY $BIIB $MRK $PFE 👀 #Biotech #Alzheimers #Phase2 #ClinicalTrials #BigPharma #IGCPharma #Bullish
0 · Reply
Latest News on IGC
IGC Pharma announced beta version of Agentic Harmonization Assistant

2026-06-23T16:59:03.000Z - 11 days ago

IGC Pharma announced beta version of Agentic Harmonization Assistant

IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow

Jun 23, 2026, 8:30 AM EDT - 11 days ago

IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow

IGC Pharma reaches 146-patient enrollment target for Phase 2 Calma trial

2026-06-11T12:43:47.000Z - 23 days ago

IGC Pharma reaches 146-patient enrollment target for Phase 2 Calma trial

IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis

Jun 11, 2026, 8:30 AM EDT - 23 days ago

IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts

Jun 9, 2026, 8:30 AM EDT - 25 days ago

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts

IGC Pharma adds Mount Sinai clinical site as CALMA trial advances

2026-06-02T15:20:34.000Z - 4 weeks ago

IGC Pharma adds Mount Sinai clinical site as CALMA trial advances

IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis

Jun 2, 2026, 8:30 AM EDT - 4 weeks ago

IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis

IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment

May 19, 2026, 5:30 PM EDT - 6 weeks ago

IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment

IGC Pharma to present new Tau-PET biomarker research at Global Tau conference

2026-05-15T13:00:12.000Z - 7 weeks ago

IGC Pharma to present new Tau-PET biomarker research at Global Tau conference

IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference

May 15, 2026, 8:00 AM EDT - 7 weeks ago

IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference

IGC Pharma Quarterly report: Q1 2026

May 15, 2026, 8:00 AM EDT - 7 weeks ago

IGC Pharma Quarterly report: Q1 2026

IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase

Apr 28, 2026, 12:15 PM EDT - 2 months ago

IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase

IGC adds Kerwin Medical Center as clinical site for Phase 2 CALMA trial

2026-04-22T13:29:55.000Z - 2 months ago

IGC adds Kerwin Medical Center as clinical site for Phase 2 CALMA trial

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

Apr 22, 2026, 8:30 AM EDT - 2 months ago

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

IGC Pharma secures Colombian authorization for psilocybin research

2026-04-20T14:17:51.000Z - 2 months ago

IGC Pharma secures Colombian authorization for psilocybin research

IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia

Apr 20, 2026, 8:30 AM EDT - 2 months ago

IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia

IGC Pharma reaches 80% enrollment in Phase 2 CALMA trial

2026-04-14T12:36:26.000Z - 2 months ago

IGC Pharma reaches 80% enrollment in Phase 2 CALMA trial

IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout

Apr 14, 2026, 8:30 AM EDT - 2 months ago

IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

Apr 8, 2026, 12:45 PM EDT - 3 months ago

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

IGC announces activation of new clinical trial sate for Phase 2 CALMA trial

2026-04-07T12:50:45.000Z - 3 months ago

IGC announces activation of new clinical trial sate for Phase 2 CALMA trial

IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease

Apr 7, 2026, 8:00 AM EDT - 3 months ago

IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease

IGC Pharma enters national media partnership with New to The Street

2026-03-30T12:38:30.000Z - 3 months ago

IGC Pharma enters national media partnership with New to The Street

IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness

Mar 30, 2026, 8:00 AM EDT - 3 months ago

IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness

IGC Pharma, New to The Street launch 12-part national media partnership

2026-03-25T12:20:15.000Z - 3 months ago

IGC Pharma, New to The Street launch 12-part national media partnership

IGC Pharma reports 9-month revenue $969K

2026-03-19T13:12:05.000Z - 3 months ago

IGC Pharma reports 9-month revenue $969K

IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025

Mar 19, 2026, 9:00 AM EDT - 3 months ago

IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025

IGC Pharma to showcase AI platform with ADDI at ADPD 2026

2026-03-18T13:10:59.000Z - 3 months ago

IGC Pharma to showcase AI platform with ADDI at ADPD 2026

IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026

Mar 18, 2026, 9:00 AM EDT - 3 months ago

IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026

IGC Pharma files utility patent applications covering AHA framework

2026-02-26T13:49:48.000Z - 4 months ago

IGC Pharma files utility patent applications covering AHA framework

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research

Feb 26, 2026, 8:30 AM EST - 4 months ago

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

Feb 24, 2026, 8:30 AM EST - 4 months ago

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

IGC Pharma expands Phase 2 CALMA trial with new clinical site

2026-02-23T13:49:20.000Z - 4 months ago

IGC Pharma expands Phase 2 CALMA trial with new clinical site

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

Feb 23, 2026, 8:30 AM EST - 4 months ago

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

IGC Pharma Transcript: Status update

Feb 18, 2026, 1:00 PM EST - 4 months ago

IGC Pharma Transcript: Status update

IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

Feb 17, 2026, 8:30 AM EST - 4 months ago

IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets

Feb 12, 2026, 8:30 AM EST - 5 months ago

IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets

IGC Pharma Announces Equity Research Update by Alliance Global Partners

Feb 10, 2026, 8:30 AM EST - 5 months ago

IGC Pharma Announces Equity Research Update by Alliance Global Partners

IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center

Feb 9, 2026, 8:30 AM EST - 5 months ago

IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation

Feb 2, 2026, 8:30 AM EST - 5 months ago

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York

Jan 22, 2026, 9:00 AM EST - 5 months ago

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia

Jan 12, 2026, 9:00 AM EST - 6 months ago

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

Jan 6, 2026, 8:00 AM EST - 6 months ago

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

Jan 5, 2026, 9:00 AM EST - 6 months ago

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

Dec 19, 2025, 9:00 AM EST - 7 months ago

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

Dec 15, 2025, 9:00 AM EST - 7 months ago

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.

Dec 10, 2025, 9:00 AM EST - 7 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Dec 9, 2025, 9:00 AM EST - 7 months ago

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

IGC Pharma Registration statement: Registration Filing

Dec 3, 2025, 7:00 AM EST - 7 months ago

IGC Pharma Registration statement: Registration Filing

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

Dec 2, 2025, 9:00 AM EST - 7 months ago

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

Nov 25, 2025, 9:00 AM EST - 7 months ago

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

IGC Pharma Earnings Call Transcript: Q3 2025

Nov 17, 2025, 11:00 AM EST - 8 months ago

IGC Pharma Earnings Call Transcript: Q3 2025

IGC Pharma Quarterly report: Q3 2025

Nov 17, 2025, 11:00 AM EST - 8 months ago

IGC Pharma Quarterly report: Q3 2025

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

Nov 17, 2025, 8:30 AM EST - 8 months ago

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

IGC Pharma Registration statement: Registration Filing

Nov 17, 2025, 7:00 AM EST - 8 months ago

IGC Pharma Registration statement: Registration Filing

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

Nov 13, 2025, 9:00 AM EST - 8 months ago

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

Nov 10, 2025, 9:00 AM EST - 8 months ago

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

Nov 3, 2025, 8:52 AM EST - 8 months ago

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

Oct 22, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

Oct 14, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

Oct 10, 2025, 7:50 PM EDT - 9 months ago

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

Oct 7, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

Sep 29, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology

Sep 24, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Sep 22, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

Sep 9, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

Sep 2, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

Aug 28, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

Aug 27, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

Aug 25, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

Aug 19, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

GordoHLYK13
GordoHLYK13 Jul. 4 at 1:44 PM
$IGC $IGC is building serious momentum. 🔥 Phase 2 CALMA is fully enrolled (146 patients), most participants have already completed the study, and the next big catalyst is the topline data readout. If results are positive, this could be a game-changing moment. Meanwhile, TGR-63 remains a promising Alzheimer’s pipeline asset, with management expected to accelerate updates after CALMA. Add in IGC’s expanding AI platform, insider alignment, and upcoming catalysts, and the setup keeps getting stronger. Eyes on CALMA. The biggest move could still be ahead. 🚀🧠💰 $IGC $LLY $BIIB $JNJ $MRK
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 8:13 AM
$IGC Bullish: CEO and PFO just converted $1.15M of debt into equity at $0.27/share instead of taking cash. That’s serious skin in the game. Their restricted Rule 144 shares mean no immediate insider dumping pressure. Balance sheet is stronger, cash is preserved, and insiders look locked & loaded ahead of the Phase 2 CALMA trial results. If the data is positive, expect a lot more eyes on igc 👀🚀 Tags: $LLY $JNJ $PFE $MRK
1 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 8:13 AM
$IGC CEO and PFO just converted $1.15M of debt into equity at $0.27/share instead of taking cash. That’s real skin in the game. Those are restricted Rule 144 shares, so there’s no immediate insider dumping pressure. They cleaned up the balance sheet, preserved cash, and look locked & loaded ahead of the upcoming Phase 2 CALMA trial results. Insiders don’t increase their equity exposure by millions of shares unless they see potential upside—but clinical trial outcomes remain uncertain until the data is released. 🚀📈 https://www.getnews.info/story/2026/07/01/igc-pharma-nyse-igc-ceo-and-cfo-acquire-more-than-42-million-shares/ $LLY $JNJ $PFE $MRK
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 3 at 6:02 PM
$IGC Not hype—just facts. 🔥 CEO & CFO converted $1.15M of debt into restricted shares, increasing insider alignment while reducing debt. With a tight float, institutional ownership, the upcoming AAIC London AI showcase, and the Phase 2 CALMA data catalyst ahead, IGC is lining up multiple potential catalysts. If the news delivers, this micro-cap could get a lot more attention. 🚀📈 $IGC #Biotech #Alzheimers #AI #SmallCaps
0 · Reply
angel6
angel6 Jul. 3 at 5:48 AM
$IGC when will the read out report be released?
1 · Reply
RocketQueen
RocketQueen Jul. 2 at 8:26 PM
$IGC good to see the CEO and CFO in FOMO mode...
0 · Reply
MrTicker
MrTicker Jul. 2 at 8:09 PM
$IGC a little volume bump after hours.. its a long weekend as the market is closed tomorrow so this could see some attention.
1 · Reply
RocketQueen
RocketQueen Jul. 2 at 6:05 PM
$IGC starting the long trail up to over 5.00 with positive results from the CALMA trial.
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 2 at 2:23 PM
$BIIB $IGC $LLY $MRK $PFE $IGC the share price is climbing because buyers are positioning ahead of the Phase 2 CALMA data. Smart money often looks to get in before potential catalysts—not after them. If CALMA delivers positive results, today’s prices could look like a bargain. 🚀🧠 #IGC #Alzheimers #Biotech
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 2 at 11:53 AM
$IGC IGC is entering its biggest catalyst yet. 🚀 Phase 2 CALMA enrollment is complete, all 146 patients are locked in, and now the market is waiting for the data. The enrollment risk is gone—it’s all about the readout. IGC-AD1 targets Alzheimer’s-related agitation, a multi-billion-dollar unmet market with very few effective treatment options. If the Phase 2 results are positive, IGC could quickly move onto the radar for licensing, partnerships, or acquisition discussions. What makes this even more interesting? IGC has funded its own clinical development, giving it flexibility if the data is strong. Positive results could attract interest from biotech and pharma leaders looking to expand their neuroscience pipelines. $LLY $BIIB $MRK $PFE 👀 #Biotech #Alzheimers #Phase2 #ClinicalTrials #BigPharma #IGCPharma #Bullish
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 2 at 11:16 AM
$IGC $HYLN take note bag holders
2 · Reply
RocketQueen
RocketQueen Jul. 2 at 4:06 AM
$IGC CFO and CEO taking on millions of shares for compensation is bullish AF.
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 2 at 2:49 AM
$IGC https://www.stocktitan.net/sec-filings/IGC/form-4-igc-pharma-inc-insider-trading-activity-e9785b886015.html Today’s insider filing says it all. Instead of draining the company’s limited cash, the CEO and CFO converted $1.15M of debt into equity, keeping cash available to finish the Phase 2 CALMA trial and data analysis. Management is betting on shares, not a paycheck—that’s confidence. Today’s 4K filing looks more like commitment than dilution. 🚀
0 · Reply
RocketQueen
RocketQueen Jul. 2 at 2:24 AM
$IGC severely under priced.
0 · Reply
NewsAndFilings
NewsAndFilings Jul. 1 at 7:28 PM
IGC Pharma (NYSE: $IGC ) CEO and CFO Acquire More Than 4.2 Million Shares https://thestreetreports.com/igc-pharma-nyse-igc-ceo-and-cfo-acquire-more-than-4-2-million-shares/
0 · Reply
Giants67
Giants67 Jul. 1 at 4:55 PM
$IGC IGA Pharma, Inc. disclosed in a Form 4 filing that two senior executives increased their ownership stakes through debt-for-equity transactions. https://thestreetreports.com/igc-pharma-nyse-igc-ceo-and-cfo-acquire-more-than-4-2-million-shares/
0 · Reply
MrTicker
MrTicker Jul. 1 at 4:49 PM
$IGC Updated Form $ .. aquired 2 million shares at .27 Form 4 IGC Pharma, Inc. For: Jun 30 Filed by: GRIMALDI CLAUDIA 10K WIZARD 8:01 AM ET 7/1/2026 http://archive.fast-edgar.com/20260701/ARLHG62CZ22HVZZ2222U2ZZPHAEPZZ22N282 Filed on: July 1, 2026
0 · Reply
RocketQueen
RocketQueen Jul. 1 at 3:20 PM
$IGC under priced. ı see this headed 5-10 USD with positive results.
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 1 at 12:10 PM
$IGC Millions of families are watching dementia stories hit the national spotlight. Every headline shines a brighter light on the urgent need for better Alzheimer’s treatments—and that’s exactly where IGC Pharma is making its move. With Phase 2 CALMA topline results expected soon, IGC has a major catalyst on the horizon. Positive data could put this micro-cap squarely on Big Pharma’s radar while bringing hope to patients and caregivers worldwide. The dementia race is just heating up. 🧠🚀 Tags: $IGC $LLY $BIIB $MRK $PFE
0 · Reply
RocketQueen
RocketQueen Jun. 30 at 3:23 PM
$IGC several irons in the fire here, but the real potential multi-bagger is positive results from the phase II data readout. Again, this is grossly underpriced and undervalued.
0 · Reply
MarketMaverickk
MarketMaverickk Jun. 30 at 2:49 PM
$IGC is making headlines again with its AI platform, and the buzz is noticeable. I wasn't expecting this much chatter on a nano-cap, but the 90% data harmonization improvement claim is a real eye-opener. Still, I’m not chasing the hype. Stalking this level to see if the market actually backs these claims with real buying pressure.
0 · Reply
NewsAndFilings
NewsAndFilings Jun. 29 at 7:18 PM
Stocks Under $1: $TNMG, $SRFM, $PRSO, $KNDI, $IGC Offer Multibagger Potential as AI Boom Accelerates https://thestreetreports.com/stocks-under-1-tnmg-srfm-prso-kndi-igc-offer-multibagger-potential-as-ai-boom-accelerates/
0 · Reply